Dextropropoxyphene
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 22 (5) , 419-432
- https://doi.org/10.2165/00002512-200522050-00006
Abstract
Dextropropoxyphene, alone or in combination with acetaminophen (paracetamol), is among the most frequently prescribed opioid analgesics in the elderly in the US despite the American Geriatric Society recommendation that its use should be restricted. However, this recommendation is based on expert opinion in an apparent absence of data. Accordingly, we conducted a literature search which identified nine studies that reported efficacy and safety data for dextropropoxyphene in predominantly older patients (≥55 years of age). These studies were evaluated to assess the efficacy and safety of dextropropoxyphene compared with other opioids and to evaluate whether safety and tolerability differed in older versus younger patients. The efficacy of dextropropoxyphene appeared to be similar to that of other analgesics, and its safety was comparable to that of other opioid analgesics. Although the adverse event profile suggests that elderly patients might have more frequent gastrointestinal and CNS complaints than younger patients treated with dextropropoxyphene, the frequency of reports appears similar to that of other opioids. The incidences of dizziness and somnolence were not significantly greater in older patients (1–2% and 0–21%, respectively) than in younger patients (8% and 13%, respectively). The absence of clinical studies directly addressing the safety and tolerability of dextropropoxyphene in elderly patients (>65 years of age) versus younger patients encumbers assessment of the validity of restricting its use in the elderly. Careful outcomes research is needed to assess the effectiveness and safety of dextropropoxyphene in older patients and to develop evidence-based risk/benefit prescribing criteria for use of this drug in this age group.Keywords
This publication has 62 references indexed in Scilit:
- Serious lower gastrointestinal clinical events with nonselective NSAID or coxib useGastroenterology, 2003
- Central Nervous System–Active Medications and Risk for Falls in Older WomenJournal of the American Geriatrics Society, 2002
- Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.Cleveland Clinic Journal of Medicine, 2002
- Single dose oral dextropropoxyphene, alone and with paracetamol (acetaminophen), for postoperative painCochrane Database of Systematic Reviews, 1999
- Acceptability and Efficacy of Two Associations of Paracetamol with a Central Analgesic (Dextropropoxyphene or Codeine): Comparison in OsteoarthritisThe Journal of Clinical Pharmacology, 1992
- The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextro-propoxyphene/paracetamol tablets in patients with severe osteoarthritis of the hipsCurrent Medical Research and Opinion, 1992
- A comparison between meptazinol and dextropropoxyphene plus paracetamol in elderly patients with musculoskeletal painsCurrent Medical Research and Opinion, 1984
- Self-poisoning with Dextropropoxyphene and Dextropropoxyphene Compounds: the USA ExperienceHuman Toxicology, 1984
- Postsurgical Pain: Zomepirac Sodium, Propoxyphene/‐Acetaminophen Combination, and PlaceboThe Journal of Clinical Pharmacology, 1981
- A comparative analgesia study of propoxyphene hydrochloride, propoxyphene napsylate, and placeboToxicology and Applied Pharmacology, 1971